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Abstract 47 
Background Syphilis in pregnancy can lead to fetal and neonatal death or congenital 48 
anomalies. Accurate on-site tests are an essential part of effective prevention of mother-to-49 
child transmission of the disease.  50 
Objective This systematic review assessed the accuracy of the on-site tests to detect infection 51 
with Treponema pallidum in pregnant women. 52 
Search strategy Major databases were searched from inception to January 2016 using terms: 53 
“pregnancy”, “antenatal”, “syphilis”, “Treponema pallidum” with their variations, and the 54 
search limit for the relevant study design. 55 
Selection criteria We included studies that used dual reference standard (non-treponemal and 56 
treponemal tests) to detected syphilis in pregnancy. 57 
Data collection and analysis Extracted accuracy data were tabulated and pooled using 58 
hierarchical, bivariate random effects model. 59 
Main results Seven studies (combined sample 17,546) reporting the accuracy of four on-site 60 
tests met the eligibility criteria. On average, Determine™ and SD BioLine Syphilis 3.0 had 61 
the highest sensitivity out of all evaluated tests 0.83 (95% CI 0.58, 0.98) and 0.86 (95% CI 62 
0.82, 0.89), respectively with a high specificity 0.96 (95% CI 0.89, 1.00) and 0.99 (95% CI 63 
0.94, 1.00), respectively. Qualitative Rapid Plasma Reagin card commonly used in clinical 64 
practice had a pooled sensitivity of 0.70 (95% CI 0.54, 0.88) and specificity of 0.97 (95% CI 65 
0.96, 0.99). 66 
Conclusion Immunochromatographic tests such as Determine and SD BioLine Syphilis 3.0 67 
seem to be acceptable options in antenatal testing for syphilis, especially in resource-limited 68 
settings. Future research should seek more evidence to strengthen this claim. 69 
Keywords Syphilis, Antenatal care, Test accuracy, On-site test 70 
Tweetable abstract On-site test to detect syphilis - options during antenatal care71 
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Introduction 72 
Syphilis, a sexually transmitted infection caused by the bacterium Treponema pallidum 73 
(T.pallidum), is endemic throughout the developing world.(1) Infection until one year is 74 
classified as early syphilis, and after one year as late syphilis. The initial manifestation of the 75 
disease can be easily overlooked and progress to the secondary stage which if undiagnosed 76 
and consequently non-treated leads to a period of latency with no visible signs of the disease. 77 
The infection is most commonly transmitted through sexual intercourse, and it can also be 78 
passed from mother to a child; in utero or during birth. 79 
 80 
Transmission of the infection had been linked with the birth of children with reactive 81 
serology, long-term congenital abnormalities, miscarriages, and fetal and neonatal deaths. 82 
(1,2) The World Health Organization (WHO) estimated that in 2008 around 1.36 million 83 
pregnant women were expected to have an active form of syphilis. Without any screening or 84 
treatment in place these women would have experienced, overall, more than 700,000 adverse 85 
outcomes where more than half would be fetal or neonatal deaths.(3) 86 
 87 
In order to prevent mother-to-child transmission of syphilis WHO advocates screening of all 88 
pregnant women antenatally and treating those identified with the disease and their 89 
partners.(4) The ideal Point-Of-Care (POC) test should be affordable, sensitive, specific, user-90 
friendly, rapid and robust, equipment free, and deliverable to those who need them. 91 
Development of POC test has made syphilis testing more accessible especially in low-92 
resource settings, as lengthy and skilled laboratory testing can be avoided.(5) 93 
Immunochromatographic tests or the on-site Rapid Plasma Reagin cards performed on-site 94 
give healthcare professionals an opportunity to administer treatment immediately and prevent 95 
the transmission of the disease.(6) 96 
 97 
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According to reviews assessing the accuracy of the immunochromatographic POC treponemal 98 
tests (7,8) they offer an alternative to laboratory-based diagnosis in resource-limited settings. 99 
However, none of the reviews focuses solely on pregnant women or compare the 100 
immunochromatographic with commonly used in clinics qualitative Rapid Plasma Reagin 101 
card which is not an ideal gold standard.(9) Our focus was to synthesise the accuracy of on-102 
site tests used in antenatal care settings to detect syphilis using an established algorithm as a 103 
reference standard.(10) 104 
 105 
Methods 106 
We conducted the review and reported our findings in compliance with the current 107 
guidelines.(11) We searched Medline, Embase, Web of Science, Scopus, and Lilacs with no 108 
language restrictions. The original search run from inception to February 2015 was updated in 109 
January 2016 (Figure 1). The literature search strategy combined clinical terms such as 110 
‘Pregnancy’, ‘Antenatal’, ‘Gestation’, ’Treponema pallidum’ and ‘Syphilis’ with a filter for 111 
test accuracy studies.(12) The detailed search strategy is available in Appendix S1. 112 
 113 
Study selection 114 
Two independent reviewers (ER and LKN) screened references and then full text of 115 
potentially relevant articles. The study had to meet following eligibility criteria: recruit 116 
pregnant women without symptoms of syphilis (chancre, rash); use as a double reference 117 
standard comprising of non-treponemal (the Rapid Plasma Reagin test or venereal disease 118 
research laboratory (VDRL)) followed by treponemal test (treponema pallidum 119 
haemagglutination assay (TPHA), fluorescent treponemal antibody-absorbed (FTA-Abs) or 120 
the treponema pallidum particle agglutination (TPPA) test). Diagnosis of recently contracted 121 
infection with T.palladium was defined as a positive result on both treponemal and non-122 
treponemal test.(13) 123 
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 124 
We excluded studies in which the population showed symptoms of syphilis, women in labour 125 
and studies where reference standard was only a treponemal or non-treponemal test. We 126 
excluded studies with a case-control design and those where it was not possible to calculate 127 
True Positives, False Positives, False Negatives and True negatives. At each stage of the 128 
review process, the consensus was reached through a discussion. In the case of a stalemate, 129 
the opinion of a third reviewer’s was sought (KSK). We did not attempt to contact the study 130 
authors for any further information. 131 
 132 
Data extraction and study quality assessment 133 
All relevant data from included studies were extracted to a standardized, and pre-piloted form. 134 
Information about the country, settings, women’s characteristics, type of index test and 135 
reference standard, and type of collected blood sample were extracted and tabulated. We 136 
classified the countries where the studies were conducted by their income following the 137 
World Bank ranking.(14) 138 
 139 
The quality of each included study was assessed by two review authors (ER, LKN) using the 140 
QUADAS-2 tool.(15) The risk of bias was evaluated for participants’ selection, use and 141 
interpretation of index test and reference standard, and participants flow and timing. First 142 
three aspects were also evaluated in the context of applicability to the review question. The 143 
review authors classified each item as “low” (sufficiently addressed), “high” (insufficiently 144 
addressed), or “unclear” (insufficient detail presented to allow judgment to be made) risk of 145 
bias. We considered a study to be of low risk of bias if; the patients were selected 146 
consecutively or randomly, the index and reference standard tests were correctly implemented, 147 
and all patients received the reference standard tests.  148 
 149 
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Data synthesis 150 
To construct two-by-two tables we extracted true positive, false positive, true negative, and 151 
false negative results or recalculated the numbers from available parameters (sensitivity, 152 
specificity, positive predictive value and negative predictive value). All analyses were 153 
performed using STATA version 12.1 (College Station, TX: StataCorp LP). Sensitivity, 154 
specificity, likelihood ratios for positive and negative test result and 95% confidence intervals 155 
(CIs) were computed for all individual studies. Where we had a sufficient number of studies 156 
(more than four), we pooled the accuracy parameters using hierarchical, bivariate, random 157 
effects model using the multilevel mixed logistic regression model as implemented by 158 
metandi command.(16) For meta-analysis with less than four studies, we pooled accuracy of 159 
sensitivity and specificity, and likelihood ratios separately using metaprop and metan 160 
commands, respectively. Between-study heterogeneity of studies was assessed graphically 161 
evaluating forest plots for sensitivity and specificity. Publication bias was not assessed due to 162 
lack of consensus over the reliability of currently available methods.(17,18)  163 
 164 
Results 165 
The database searches retrieved 2,045 relevant citations; additional eight records were 166 
identified through the reference check. Out of 59 potentially relevant articles evaluated by 167 
their full text, seven publications met the eligibility criteria (Figure 1). A detailed list of 168 
excluded studies with reasons for their exclusion can be found in Table S1.   169 
 170 
Characteristics of included studies 171 
Eligible studies recruited combined number of 17,546 pregnant women. The prospective 172 
studies were published between 1993 and 2015, with seroprevalence of syphilis ranging from 173 
1 - 11%. In three publications authors didn’t mention in the text whether women were 174 
previously treated for syphilis,(19-21) one excluded this group (22), and in the remaining 175 
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studies around 7% of participants were previously diagnosed with syphilis.(23-25) Included 176 
publications reported accuracy data of three immunochromatographic tests: Determine™ 177 
(Abbott Laboratories, Chicago, USA), SD BioLine Syphilis 3.0 (Standard Diagnostics Inc., 178 
Republic of Korea), VisiTect Syphilis (Omega Diagnostics, Alloa, Scotland) and the 179 
qualitative Rapid Plasma Reagin card (multiple manufacturers). The majority of studies 180 
recruited women in hospital settings,(19,20,22,23,25) one in primary care (24) and one in the 181 
general health centre (21). Three studies were conducted in upper-middle income countries, 182 
two in lower-middle income countries and two studies were in low-income countries (Table 183 
1). All studies used fresh blood samples. 184 
 185 
Quality assessment 186 
Six out of seven studies had an unclear risk of bias for the sample selection due to a lack of 187 
information about the selection process. The majority of studies were assessed as low risk of 188 
bias for the implementation of the reference standard and all for the index test. The bias for 189 
flow and timing was unclear in two studies due insufficient level of information (Table 2). 190 
One study (25) was classified as of high concern over applicability in sample selection as it 191 
reports physical examination findings of participants (Table 2). There was no overall concern 192 
applicability of included studies in terms of index test and applied reference standard. 193 
 194 
Accuracy of immunochromatographic tests 195 
Two studies (20,24) with a combined sample size of 9,587 women reported accuracy data of 196 
the Determine™ test. Pooled sensitivity and specificity of the Determine™ were 0.83 (95% 197 
CI 0.58, 0.98) and 0.96 (95% CI 0.89, 1.00), respectively with likelihood ratio for the positive 198 
test of 24.88 (95% CI 4.19, 147.57), and for a negative test result of 0.16 (95% CI 0.04, 0.66). 199 
Two studies (22,25) reported the data on the accuracy of the SD BioLine Syphilis 3.0. Pooled 200 
sensitivity from those studies was of 0.86 (95% CI 0.82, 0.89), and sensitivity of 0.99 (95% 201 
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CI 0.94, 1.00). The likelihood ratio for the positive and negative test result was 54.87 (95% CI 202 
6.52, 461.65) and 0.15 (95% CI 0.12, 0.20), respectively. The accuracy of the third test, 203 
VisiTect Syphilis, was reported in one study of 712 women. (23) The sensitivity of VisiTect 204 
was 0.63 (95% CI 0.31, 0.86) and specificity 0.98 (95% CI 0.97, 0.99).  205 
 206 
Qualitative Rapid Plasma Reagin card 207 
The qualitative Rapid Plasma Reagin test was used as an index test in five studies. (19-208 
21,23,25) Pooled sensitivity was 0.70 (95% CI 0.50, 0.84) and pooled specificity 0.97 (95% 209 
CI 0.96, 0.98). The derived likelihood ratio of the positive test result was 27.07 (95% CI 210 
15.39, 47.61) and the negative result of 0.31 (95%CI 0.17, 0.56). There was visible greater 211 
heterogeneity between sensitivity estimates than specificity with the 95% predictive region 212 
covering less than one-third of the operating space (Figure S1). The accuracy parameters of 213 
all evaluated tests have been collated and summarised in Table 3. The numbers used to 214 
calculate the parameters are available in Table S2. 215 
 216 
Discussion 217 
Main findings 218 
SD BioLine Syphilis 3.0 test had, on average, the highest sensitivity out of all evaluated 219 
immunochromatographic tests, and visibly higher sensitivity than qualitative Rapid Plasma 220 
Reagin card. Specificity did not differ significantly between the identified tests.  221 
 222 
Strengths and limitations  223 
This systematic review was conducted using following current methodological standards.(11) 224 
The use of search limit for test accuracy studies (12), was a pragmatic choice. The search 225 
without the limit had too-broad approach to be practicable. Even though, we identified the 226 
majority of studies with antenatal population included in the previous reviews and two 227 
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additional ones (19,22) the overall number of studies available for the analyses was small. 228 
The bivariate analysis was possible only for the RPR card, yet its findings are weakened by a 229 
visible heterogeneity of sensitivity parameters between the individual studies. 230 
 231 
Test accuracy studies are prone to numerous sources of bias due to patients’ selection and 232 
retention in the study, implementation of the index test and reference standard. In our review, 233 
we managed to limit spectrum bias by excluding studies with case-control design. However, 234 
the majority of included studies failed to describe recruitment method and inclusion criteria. 235 
 236 
The risk of bias and concern over the applicability of the index tests and reference standards 237 
were generally low. Ideally, the reference standard and the index test should be entirely 238 
independent of each other.(26) This was true for the immunochromatographic test, yet the 239 
lab-based confirmatory algorithm for the qualitative Rapid Plasma Reagin card had as its non-240 
treponemal component quantitative Rapid Plasma Reagin test. This raises concern over an 241 
incorporation bias (26), however, the extent to which use of the Rapid Plasma Reagin test as a 242 
part of gold standard could distort the results is unclear, and couldn’t be avoided due to 243 
studies’ design. 244 
 245 
The average prevalence of double reactive sera in studies evaluating the accuracy of 246 
Determine™, SD BioLine Syphilis 3.0, VisiTect Syphilis and the qualitative Rapid Plasma 247 
Reagin card were 4.0%, 8.2%, 1.1% and 5.7%, respectively. This level of prevalence is higher 248 
than the global prevalence of the disease among antenatal care attendee and in some cases 249 
(South Africa or Senegal) even significantly higher than in the countries where the studies 250 
were conducted.(27) By definition, sensitivity and specificity do not depend on the disease 251 
prevalence. However, their parallel variability can occur due to clinical or artefactual 252 
mechanisms.(28) Clinicians before drawing any conclusion basing on the accuracy findings 253 
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should be very clear about the clinical question they want to address. The diversity of the 254 
prevalence, statistical methods used to pool the data and the quality of reporting impacts the 255 
generalisability of presented findings. 256 
 257 
The timely delivery of treatment during prenatal period alters the risk of adverse outcomes 258 
due to syphilis infection. (29) In order to optimise the applicability of our findings to the 259 
context of antenatal care, we defined a clear research question. We focused solely on pregnant 260 
women during the perinatal period. We looked for the immunochromatographic, in detecting 261 
double positive sera to non-treponemal and treponemal components of the reference standard.  262 
 263 
Interpretation 264 
Two previous reviews address the issue of accuracy of the rapid, on-site testing using 265 
different methods of data synthesis.(7,8) The first review found that the 266 
immunochromatographic tests have a high sensitivity and higher specificity comparable with 267 
parameters of non-treponemal.(8) In systematic review with Bayesian approach to data 268 
synthesis the Determine test had the highest sensitivity when comparing with T.palladium 269 
specific reference standard. However, the authors admitted in their work that due to applied 270 
methodology the values of sensitivity were overestimated.(7) Both reviews included women 271 
tested in antenatal care settings, including women in labour, and focusing on the accuracy and 272 
value of the immunochromatographic test in rapid testing for syphilis.  273 
 274 
Similar to the previous reviews (7, 8), the immunochromatographic tests were characterised 275 
by high sensitivity and specificity. Additionally, their average sensitivity was higher than for 276 
the qualitative Rapid Plasma Reagin on-site card (except VisiTech Syphilis) with the average 277 
specificity comparable between all the tests. The immunochromatographic tests are 278 
comparable in cost (8) and easier to operate than Rapid Plasma Reagin card (21,24) what 279 
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makes them less prone to an operator error. The average cost in low resource settings is U.S. 280 
$0.91 and U.S. $1.05 for the RPR and ICS tests. (8) Nonetheless, their reliability depends on 281 
the background proportion of women with past-treated infection who may still test as positive, 282 
and consequently be treated unnecessarily. Furthermore, the tests can also give a positive 283 
result in various no venereal treponematoses such as yaws and pinta, these would be 284 
considered false positive results and are preferred to false negative results and there is greater 285 
benefit in over-treating all patients with positive results as opposed to the alternative. 286 
 287 
In the high-prevalence settings (assumed 11%) around 9% of all positive tests with SD 288 
BioLine Syphilis 3.0 would be falsely positive in contrast to 21 – 28% with the other 289 
immunochromatographic tests or the Rapid Plasma Reagin card. The proportion of potentially 290 
missed cases would be 2% for SD BioLine Syphilis 3.0 and Determine™, and 4% for 291 
VisiTech and Rapid Plasma Reagin card. Syphilis in pregnancy is effectively treated with 292 
penicillin  with benzathine penicillin remaining the first-line therapy for early syphilis. (30) 293 
The treatment is administered by intramuscular injection and requires three large doses once 294 
weekly for three weeks. This requires patients to return to health care services for each dose 295 
which may prove difficult in rural settings. With no cases of antibiotic resistance reported so 296 
far (31) prevention of mother-to-child transmission of the disease is more important than 297 
overtreatment. 298 
 299 
Conclusion 300 
Our systematic review adds to the current body of evidence on the accuracy of the rapid and 301 
Point-of-Care test to detect infection with T.palladium in the context of the antenatal care. 302 
Future test accuracy studies should aim to improve reporting of their findings and directly 303 
compare the accuracy of available test controlling for the confounders. 304 
 305 
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When testing anntenatally for syphilis immunochromatographic tests such as Determine™ 306 
and SD BioLine Syphilis 3.0 seem to be acceptable options. However, future research is 307 
needed to provide more evidence to strengthen this claim. 308 
 309 
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Table 1 Characteristics of studies of on-site tests to detect syphilis among pregnant women 
Study ID Country Settings Sample size Reference standard 
Type of the  
index test Index test 
Type of 
blood sample 
Sero-prevalence* 
(95% CI) 
Benzaken 
2011 
Brazil Antenatal 
clinic 
712 VDRL FTA-Abs Treponemal test  
- ICS 
VisiTect Syphilis test Whole blood 0.01 (0.01, 0.02) 
Bronzan 
2007 
South Africa Primary 
Care clinic 
1,250 Quantitative 
RPR 
TPHA Treponemal test  
- ICS 
Determine™ Whole blood 0.06 (0.05, 0.08) 
Non-treponemal test 
- RPR 
Qualitative RPR card Whole blood 
Delport 
1993 
South Africa Antenatal 
clinic 
1,237 Quantitative 
RPR 
TPHA Non-treponemal test 
-RPR 
Qualitative RPR card Plasma 0.07 (0.05, 0.08) 
Kashyap 
2015 
India University 
Hospital 
200 VDLR TPHA Treponemal test  
- ICS 
SD BioLine Syphilis Serum 0.02 (0.01, 0.05) 
Montoya 
2006 
Mozambique Antenatal 
clinic 
4,789 Quantitative 
RPR 
TPHA Treponemal test 
- ICS 
SD BioLine Syphilis Whole blood 0.08 (0.08, 0.09) 
Non-treponemal test 
- RPR 
Qualitative RPR card Whole blood 
Tinajeros 
2006 
Bolivia Maternity 
Hospital 
8,892 Qualitative 
RPR 
TPPA Treponemal test  
- ICS 
Determine™ Whole blood 0.04 (0.03, 0.04) 
Non-treponemal test 
- RPR 
Qualitative RPR card Serum 
Van Dyck 
1993 
Senegal Health 
Centre 
466 Quantitative 
RPR 
TPHA/ 
FTA-
Abs** 
Non-treponemal test 
- RPR 
Qualitative RPR card Whole blood 0.11 (0.08, 0.14) 
*reactive both non-treponemal and treponemal tests; ** on discordant samples 
RPR - Rapid Plasma Reagin 
ICS - Immunochromatographic strip  
FTA-Abs - Fluorescent treponemal antibody absorption 
TPHA - Treponema pallidum hemagglutination assay 
TPPA - Treponema pallidum particle agglutination assay 
VDRL - Venereal disease research laboratory  
Table 2 Quality assessment of included studies using QUADAS-2 tool 
QUADAS Risk of bias  Concern over applicability  
Study ID Sample selection 
Index 
test 
Referenc
e 
standard 
Flow 
and 
timing 
Sample 
selection 
Index 
test 
Referenc
e 
standard 
Benzaken 2011 Low Low Low Low Unclear Low Low 
Bronzan 2007 Unclear Low Low Low Unclear Low Low 
Delport 1993 Unclear Low Low Unclear Unclear Low Low 
Kashyap 2015 Unclear Low Unclear Low Low Low Low 
Montoya 2006 Unclear Low Low Low High Low Low 
Tinajeros 2006 Unclear Low Low Unclear Unclear Low Low 
Van Dyck 1993 Unclear Low Low Low Unclear Low Low 
Table 3 Accuracy of tests to detect syphilis among pregnant women 
Index test Study ID Reactive/  Non-reactive 
Sensitivity  
(95%CI) 
Specificity  
(95%CI) 
Likelihood ratio for a 
positive test result 
(95%CI) 
Likelihood ratio for 
a negative test result 
(95%CI) 
Determine Tinajeros 2006 342/8,850 0.92 (0.88, 0.95) 0.99 (0.98, 0.99) 61.33 (51.49, 73.04) 0.08 (0.06, 0.12) 
Bronzan 2007^ 44/651 0.70 (0.56, 0.82) 0.93 (0.91, 0.95) 9.97 (7.11, 13.98) 0.32 (0.20, 0.50) 
 Pooled estimates 386/9,201 0.83 (0.58, 0.98) 0.96 (0.89, 1.00) 24.88 (4.19, 147.57) 0.16 (0.04, 0.66) 
SD BioLine 
Syphilis 3.0 
Montoya 2006 381/4,105 0.86 (0.82, 0.89) 0.97 (0.96, 0.97) 26.41 (22.23, 31.37) 0.15 (0.12, 0.19) 
Kashyap 2015 4/196 0.75 (0.30, 0.95) 1.00 (0.98, 1.00) 275.80 (16.32, 4660.18) 0.30 (0.08, 1.15) 
 Pooled estimates 385/4,301 0.86 (0.82, 0.89) 0.99 (0.94, 1.00) 54.87 (6.52, 461.65) 0.15 (0.12, 0.20) 
VisiTech Syphilis Benzaken 2011^^ 8/704 0.63 (0.31, 0.86) 0.98 (0.97, 0.99) 40.00 (18.07, 88.57) 0.38 (0.16, 0.93) 
Qualitative Rapid 
Plasma Reagin 
card 
Bronzan 2007^ 35/520 0.46 (0.29, 0.63) 0.97 (0.95, 0.98) 14.86 (8.13, 27.14) 0.56 (0.41, 0.76) 
Van Dyck 1993 50/402 0.46 (0.32, 0.61) 0.97 (0.94, 0.98) 13.21 (7.28, 23.97) 0.56 (0.43, 0.72) 
 Montoya 2006 381/4,105 0.71 (0.67, 0.76) 0.96 (0.96, 0.97) 19.80 (16.70, 23,48) 0.30 (0.25, 0.35) 
 Tinajeros 2006 342/8,847 0.76  (0.71, 0.80) 0.99 (0.99, 0.99) 82.98 (66.01, 104.33) 0.25 (0.20, 030) 
 Delport 1993 83/1,154 0.93 (0.85, 0.97) 0.96  (0.95 ,0.97) 24.90 (18.46, 33.59) 0.75 (0.04, 0.16) 
 Pooled estimates 891/14,728 0.70 (0.50, 0.84) 0.97 (0.96, 0.98) 27.07 (15.39, 47.61) 0.31 (0.17, 0.56) 
^ combined high & low titre (both define active syphilis) 
^^ Missing VDRL samples assumed as positive 
